Cancer Monoclonal Antibodies Market Size, Share, Growth Analysis, By Type (Human, Chimeric), By Application (Blood Cancer, Breast Cancer), By End-user (Hospitals, Research Institutes), By Region - Industry Forecast 2025-2032

Cancer Monoclonal Antibodies Market size was valued at USD 87.5 Billion in 2023 and is poised to grow from USD 103.6 Billion in 2024 to USD 400.1 Billion by 2032, growing at a CAGR of 18.40% during the forecast period (2025-2032).

Along with radiation, chemotherapy, and surgery, monoclonal antibody-based immunotherapy is a vital part of the treatment arc for cancer. Over the last 20 years, it has been observed that mAbs have been featured as one of the most effective classes of treatments for both solid tumors and hematologic malignancies. Increasing incidence of cancer, new medication approvals, strong pipelines, and these trends are the main attractions that drive the market expansion. Present and upcoming therapies using monoclonal antibodies may help several millions of people globally. In addition, mAbs have fewer side effects on a patient's body compared to chemotherapy. Furthermore, increasing the adoption of more affordable biosimilar monoclonal antibodies by physicians and oncologists would further facilitate the market during the forecast period. Admittedly, severe cancer screening declined due to limited access to health systems to fight against the epidemic. For example, in April 2020, an 87% decline in breast cancer screening compared to the average for the same month during the prior five years was shown. This forced many cancer patients to delay or extend their treatment, raising concerns over access to the cancer drugs in time, recurrence of the disease, and cancelation of the cancer therapies. Cancer is a class of chronic diseases that is marked by uncontrolled cell growth. The growing incidence of cancer is predicted to act as a driver for market growth and demand for monoclonal antibodies.